Characterization of a PERK Kinase Inhibitor with Anti-Myeloma Activity

Characterization of a PERK Kinase Inhibitor with Anti-Myeloma Activity

Due to increased immunoglobulin production and uncontrolled proliferation, multiple myeloma (MM) plasma cells develop a phenotype of deregulated unfolded protein response (UPR). The eIF2-alpha kinase 3 [EIF2αK3, protein kinase R (PKR)-like ER kinase (PERK)], the third known sensor of endoplasmic ret...

Full description

Bibliographic Details
Main Authors: Tina Bagratuni, Dimitrios Patseas, Nefeli Mavrianou-Koutsoukou, Christine Ivy Liacos, Aimilia D. Sklirou, Pantelis Rousakis, Maria Gavriatopoulou, Evangelos Terpos, Ourania E. Tsitsilonis, Ioannis P. Trougakos, Efstathios Kastritis, Meletios A. Dimopoulos
Format: Article
Language:English
Published: MDPI AG 2020-10-01
Series:Cancers
Subjects:
apoptosis
bortezomib
cell survival
multiple myeloma
PERK
UPR
Online Access:https://www.mdpi.com/2072-6694/12/10/2864

Internet

https://www.mdpi.com/2072-6694/12/10/2864

Similar Items